Northern Trust Corp Trims Stock Holdings in Pediatrix Medical Group, Inc. $MD

Key Points

• Northern Trust Corp reduced its holdings in Pediatrix Medical Group by 2.1%, selling 20,347 shares and retaining a total of 946,000 shares worth approximately $13.7 million.
• Pediatrix Medical Group reported a EPS of $0.53 for the latest quarter, exceeding analysts' expectations, despite a 7.1% decline in quarterly revenue year-over-year.
• Wall Street analysts have a "Moderate Buy" rating for Pediatrix Medical Group, with an average price target of $16.75, reflecting optimism about the company's performance.

Northern Trust Corp lessened its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 2.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 946,000 shares of the company's stock after selling 20,347 shares during the quarter. Northern Trust Corp owned about 1.10% of Pediatrix Medical Group worth $13,708,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its position in Pediatrix Medical Group by 218.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,445 shares of the company's stock valued at $98,000 after acquiring an additional 5,104 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Pediatrix Medical Group by 9.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 77,393 shares of the company's stock valued at $1,016,000 after acquiring an additional 6,753 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Pediatrix Medical Group by 87.8% in the 4th quarter. BNP Paribas Financial Markets now owns 34,776 shares of the company's stock valued at $456,000 after acquiring an additional 16,256 shares in the last quarter. Bayesian Capital Management LP bought a new position in Pediatrix Medical Group in the 4th quarter valued at about $190,000. Finally, Bridgeway Capital Management LLC lifted its position in Pediatrix Medical Group by 2.6% in the 4th quarter. Bridgeway Capital Management LLC now owns 545,445 shares of the company's stock valued at $7,156,000 after acquiring an additional 13,607 shares in the last quarter. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock traded down $0.03 during trading on Tuesday, hitting $16.93. The stock had a trading volume of 80,388 shares, compared to its average volume of 756,071. Pediatrix Medical Group, Inc. has a 1 year low of $10.29 and a 1 year high of $17.67. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.70. The stock's 50 day moving average is $14.51 and its two-hundred day moving average is $14.12. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of 13.12 and a beta of 1.29.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.42 by $0.11. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The business had revenue of $468.84 million for the quarter, compared to the consensus estimate of $464.37 million. During the same quarter in the prior year, the business earned $0.34 earnings per share. Pediatrix Medical Group's revenue for the quarter was down 7.1% on a year-over-year basis. As a group, analysts predict that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Leerink Partners raised their price target on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a "market perform" rating in a research report on Friday. UBS Group lifted their target price on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. Finally, Zacks Research raised shares of Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.79.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.